Scarica l'app Stockscreener
1.78
3.49%
0.06
Precedente Chiudi:
$1.72
Aprire:
$1.86
Volume 24 ore:
1.57M
Relative Volume:
2.66
Capitalizzazione di mercato:
$139.50M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.73%
1M Prestazione:
-4.30%
6M Prestazione:
+175.54%
1 anno Prestazione:
+64.81%
Intervallo 1D:
$1.7797
$2.25
Intervallo di 1 settimana:
$1.68
$2.25
Portata 52W:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Nome
Citius Oncology Inc
Settore
Telefono
(908) 967-6677
Indirizzo
11 COMMERCE DRIVE, CRANFORD
Confronta CTOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.78 | 141.97M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
143.65 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.92 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.205 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.77 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
430.10 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-11-27 | Iniziato | Maxim Group | Buy |
Citius Oncology Inc Borsa (CTOR) Ultime notizie
Real time breakdown of Citius Oncology Inc. stock performance2025 Market Overview & Verified High Yield Trade Plans - newser.com
How Citius Oncology Inc. stock benefits from tech adoption2025 Sector Review & Accurate Entry/Exit Alerts - newser.com
Citius Oncology Inc. stock prediction for this weekJuly 2025 News Drivers & Real-Time Buy Signal Alerts - newser.com
What analysts say about Citius Oncology Inc stockCurrency Fluctuation Impact & High Return Wealth Building - earlytimes.in
Why Citius Oncology Inc. stock is recommended by analysts2025 Analyst Calls & Reliable Trade Execution Plans - newser.com
Sector ETF performance correlation with Citius Oncology Inc.Trade Analysis Summary & Short-Term High Return Strategies - newser.com
What to do if you’re stuck in Citius Oncology Inc.Trade Volume Report & High Return Stock Watch Alerts - newser.com
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Is Citius Oncology Inc. stock attractive for long term wealth buildingBuy Signal & Fast Moving Stock Watchlists - newser.com
Is Citius Oncology Inc. stock bottoming out2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Is it too late to sell Citius Oncology Inc.July 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
Is Citius Oncology Inc. a candidate for recovery playStock Surge & Safe Swing Trade Setup Alerts - newser.com
Heatmap analysis for Citius Oncology Inc. and competitors2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Citius Oncology's (CTOR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How Citius Oncology Inc. stock performs in stagflationTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
Will a bounce in Citius Oncology Inc. offer an exitMarket Movement Recap & Safe Entry Zone Identification - newser.com
Has Citius Oncology Inc. formed a bullish divergenceVolume Spike & Daily Volume Surge Signals - newser.com
Is it time to cut losses on Citius Oncology Inc.Trade Volume Report & Real-Time Stock Price Movement Reports - newser.com
Citius in talks over Lymphir access in global markets - The Pharma Letter
Citius Oncology expands LYMPHIR access through named patient programs By Investing.com - Investing.com Canada
Citius Sets Up Access to Lymphir in Southern Europe - MarketScreener
Citius Oncology expands LYMPHIR access through named patient programs - Investing.com
Citius Oncology enters exclusive distribution agreement with Integris Pharma S.A. - MarketScreener
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Decline in Short Interest - Defense World
Is a relief rally coming for Citius Oncology Inc. holdersWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
Can volume confirm reversal in Citius Oncology Inc.July 2025 Highlights & Low Risk Entry Point Tips - newser.com
Using data tools to time your Citius Oncology Inc. exit2025 Earnings Impact & Technical Analysis for Trade Confirmation - newser.com
What MACD and RSI say about Citius Oncology Inc.Trade Risk Report & Long-Term Safe Return Strategies - newser.com
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Down 55.2% in September - MarketBeat
Citius Oncology (NASDAQ:CTOR) and Structure Therapeutics (NASDAQ:GPCR) Head to Head Survey - Defense World
Citius Oncology Inc Azioni (CTOR) Dati Finanziari
Non sono disponibili dati finanziari per Citius Oncology Inc (CTOR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):